

Apple Health PDL Drug Class Motions

Anticonvulsants

- ▶ AMPA Glutamate Receptor Antagonists
- ▶ Benzodiazepines - Rescue Agents
- ▶ Misc
- ▶ Succinimides

Anticonvulsants

Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Taylor**
- ▶ **2nd: Flynn**

Antidementia Agents

- ▶ Antidementia Agents
- ▶ Anti-Amyloid Antibodies

Antidementia Agents

Motion: I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Beste**
- ▶ **2nd: Flynn**

Asthma and COPD Agents

- ▶ Anticholinergics
- ▶ Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- ▶ Long Acting Muscarinic Agents
- ▶ Monoclonal Antibodies
- ▶ Phosphodiesterase 4 Inhibitors

Asthma and COPD Agents

Motion: I move that all products in the drug classes listed on slide 6 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Flynn**
- ▶ **2nd: Pope**

Atopic Dermatitis Agents

- ▶ Janus Kinase (JAK) Inhibitors – Oral
- ▶ Janus Kinase (JAK) Inhibitors – Topical
- ▶ Monoclonal Antibodies
- ▶ Phosphodiesterase 4 Inhibitors - Topical

Atopic Dermatitis Agents

Motion: I move that all products in the drug classes listed on slide 8 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Hudson**
- ▶ **2nd: Park**

Cytokine and CAM Antagonists

- ▶ **Motion:** I move that all products in the Cytokine and CAM Antagonists class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Beste**
- ▶ **2nd: Pope**

Hematopoietic Agents

- ▶ Erythroid Maturation Agents
- ▶ Erythropoiesis-Stimulating Agents (ESAS)
- ▶ Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
- ▶ Granulocyte Colony-Stimulating Factors (G-CSF)

Hematopoietic Agents

Motion: I move that all products in the drug classes listed on slide 11 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Taylor**
- ▶ **2nd: Flynn**

Neuromuscular Agents : Muscular Dystrophy Agents

- ▶ **Motion:** I move that all products in the Neuromuscular Agents : Muscular Dystrophy Agents class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Pope**
- ▶ **2nd: Flynn**

Oncology Agents

- ▶ Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral
- ▶ Autologous Cellular Immunotherapy (CAR-T)

Oncology Agents

Motion: I move that all products in the drug classes listed on slide 14 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Flynn**
- ▶ **2nd: Pope**

AHDPL Classes

- ▶ Asthma and COPD Agents
 - ▶ Inhaled Corticosteroid Combinations
 - ▶ Inhaled Corticosteroids
- ▶ Atopic Dermatitis Agents
 - ▶ Immunosuppressive Agents - Topical
- ▶ Corticosteroids
 - ▶ Glucocorticosteroids - Oral
- ▶ Hematopoietic Agents
 - ▶ Gaucher Disease
 - ▶ Sickle Cell Anemia
 - ▶ Sickle Cell Anemia - Selectin Blockers

AHDPL Classes

▶ Oncology Agents

- ▶ Alkylating Agents – Oral
- ▶ Antiadrenals – Oral
- ▶ Antiestrogens – Oral
- ▶ Antimetabolites – Oral
- ▶ Antineoplastic Estrogens – Oral
- ▶ Antineoplastics Misc – Oral
- ▶ BCL-2 Inhibitors – Oral
- ▶ Gene Therapies
- ▶ Histone Deacetylase Inhibitors – Oral
- ▶ Imidazotetrazines – Oral

AHDPL Classes

▶ Oncology Agents

- ▶ Immune Modulators
- ▶ Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral
- ▶ Janus Associated Kinase (JAK) Inhibitors – Oral
- ▶ Mitotic Inhibitors – Oral
- ▶ Nitrogen Mustards – Oral
- ▶ Nitrosoureas – Oral
- ▶ Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral
- ▶ Proteasome Inhibitors – Oral
- ▶ Selective Retinoid X Receptor Agonists – Oral
- ▶ XPO1 Inhibitors - Oral

AHDPL Classes

Motion: I move that all products in the drug classes listed on slides 16, 17 and 18 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Barkett**
- ▶ **2nd: Hudson**